Sunho Biologics

2898 · HKEX

Public Market Listing

2898HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Sunho Biologics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
PD-1 x IL-15/IL-15Rα complexProtein / enzyme therapeutic
Non-Small Cell Lung Cancer
Phase 1
FGF21 receptorProtein / enzyme therapeutic
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
August 2029 (1)
IAP0971Phase 1/2Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer
Est. primary completion 2029-08-01 · NCT06581419 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1——$24M$5.3Mreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M—$11M$11Mreport ↗

Sunho Biologics reported revenue of $0.01M, cash and equivalents of $10.82M, and a quarterly net burn of $11.13M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text